《新股》不同集團(06090.HK)孖展超購增至2,225.5倍 奇瑞汽車(09973.HK)孖展暫超購11.7倍
經營母嬰品牌BeBeBus的不同集團(06090.HK)招股期將於今日(18日)中午完結,截至今早約9時半,各券商合共為其借出孖展額已增至1,740.8億元,孖展超購倍數增至2,225.5倍。不同集團定於下周二(23日)上市,由中信証券及海通國際擔任聯席保薦人。
同期招股的內地汽車生產商奇瑞汽車(09973.HK)的招股期進入第二日,綜合市場數據,截至今早約9時半,多間券商累計借出孖展額逾116億元,以公開發售部分最多集資約9.15億元計,暫時超額認購11.7倍。奇瑞汽車的招股期將於下周一(22日)中午結束,預料下周四(25日)於聯交所上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.